Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL
Official Title: Randomized Phase II Study of Belumosudil vs. Placebo for Preemptive Treatment of Chronic Graft Versus Host Disease
Brief Summary: This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease.
Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems.
Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease.
Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the need for starting additional immune suppressive medications.